DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Tysabri (Natalizumab) - Current Clinical Trials

 
 



Tysabri Related Clinical Trials

A Proof of Concept Study to Evaluate the Effectiveness of Tysabri in Relapsing Remitting Multiple Sclerosis (RRMS) Patient Bladder Function [Completed]

Effect of Tysabri in Patients With Relapsing-Remitting Multiple Sclerosis: A Follow-up Magnetization Transfer Imaging (MTI) Study [Completed]

Effects of Tysabri (BG00002) Over 12 Months on MS Related Fatigue in Participants With RRMS [Completed]

Safety Study of Natalizumab to Treat Multiple Sclerosis (MS) [Completed]

Tysabri Effects on Cognition and Neurodegeneration in Multiple Sclerosis [Recruiting]

Natalizumab (BG00002, Tysabri) Study in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) [Completed]

The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis [Completed]

Natalizumab High Titer Immunogenicity and Safety [Completed]

Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS) [Completed]

A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (TysabriŽ) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients [Completed]

Natalizumab De-escalation With Interferon Beta-1b [Completed]

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis [Active, not recruiting]

Phase II Trial of Natalizumab (TysabriŽ) Plus Prednisone for Initial Therapy of Acute Graft Versus Host Disease (aGVHD) of the Gastrointestinal Tract [Recruiting]

Natalizumab Subcutaneous Immunogenicity and Safety Study [Terminated]

Open-Label Natalizumab Safety Extension Study [Completed]

Natalizumab in Inclusion Body Myositis (IBM) [Recruiting]

Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosis [Completed]

Natalizumab Treatment of Progressive Multiple Sclerosis [Completed]

NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or Sleepiness [Completed]

Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis [Completed]

Study to Assess Immune Function and MRI Disease Activity in RRMS Patients When Switching From Natalizumab to Gilenya [Recruiting]

Cognitive Evolution in Tysabri Treated Multiple Sclerosis Patients [Completed]

A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-a [Withdrawn]

Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis [Completed]

Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis (MS) After Failure on Other Therapies [Recruiting]

Natalizumab in the Treatment of Rheumatoid Arthritis in Subjects Receiving Methotrexate [Terminated]

Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease [Not yet recruiting]

Observational Study to Assess the Correlation of EDSS With Quality of Life in MS Participants Treated With Natalizumab [Recruiting]

Natalizumab (Tysabri) Re-Initiation of Dosing [Terminated]

Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab) [Completed]

Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants [Recruiting]

Safety and Efficacy in Pediatric MS Patients Prescribed Tysabri [Active, not recruiting]

JC-Virus (JCV) Antibody Program [Completed]

TYGRIS - ROW: TYSABRI Global Observational Program in Safety - Rest of World [Completed]

Difference in Efficacy of Natalizumab Versus Fingolimod for the Treatment of Multiple Sclerosis [Recruiting]

Cognitive Evolution in Tysabri Treated Multiple Sclerosis Patients - A Three Year Extension [Recruiting]

Disease Control in RRMS Transferring Treatment From Natalizumab to Fingolimod [Recruiting]

Evaluation of Natalizumab for thE Relief of MS Associated FatiGue [Completed]

Neurocognitive Changes in Patients With Remitting Relapsing Multiple Sclerosis Treated With Natalizumab [Not yet recruiting]

Canadian Multicenter Observational Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants [Recruiting]

Safety and Efficacy of Natalizumab in Combination With Remicade in the Treatment of Crohn's Disease [Completed]

Safety, Tolerability and Effectiveness of Natalizumab in Adolescents With Active Crohn's Disease [Completed]

Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease [Completed]

Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease [Completed]

Magnetic Resonance Imaging (MRI) Follow-up of Macrophagic Infiltration in MS Patients Treated With Tysabri [Terminated]

Impact Study of 2 Therapeutic Strategy for Aggressive Remitting Multiple Sclerosis [Recruiting]

Alternative Treatment Paradigm for Natalizumab Trial [Withdrawn]

Analysis of Lymphocyte Cell Surface Adhesion Marker Expression in Natalizumab Population With Active Control [Completed]

Differential Immune Effects of Natalizumab [Completed]

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative Participants [Active, not recruiting]

A Clinical Trial of Natalizumab in Individuals With Moderately to Severely Active Crohn's Disease [Completed]

Safety and Effectiveness of Switching Relapsing MS Patients Treated With Natalizumab at Risk for PML to Teriflunomide [Recruiting]

Pilot Study to Assess Disease Stability in a Natalizumab to Dimethyl Fumarate Crossover Design [Active, not recruiting]

JC Virus Reactivation in Multiple Sclerosis [Active, not recruiting]

Corticosteroids for Immune Reconstitution Inflammatory Syndrome (IRIS) [Terminated]

A Study of MSDx Complex 1 as a Marker for Therapy Response in Multiple Sclerosis [Recruiting]

Genetic Evaluation of Natalizumab-Treated Patients With Progressive Multifocal Leukoencephalopathy [Terminated]

Longitudinal Analysis And Sample Collection To Evaluate PML Risk Host Markers for PML Risk Host Markers for PML Risk [Recruiting]

Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study [Recruiting]

Preliminary Study for Selective Detection of the CD8+ Myelin Specific T Cell in the Blood of Multiple Sclerosis Patients [Active, not recruiting]

Safety and Efficacy of Alemtuzumab in Pediatric Intestinal Transplantation [Active, not recruiting]

A Cross-Sectional Study of MSDx Complex 1 as a Marker for Active Disease in Multiple Sclerosis [Recruiting]

Anal Dysplasia in Patients With Inflammatory Bowel Disease and Healthy Controls [Completed]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015